Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in children with chronic kidney disease
PACTR202511687575219Phase 2Recruiting
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of dapagliflozin in chronic kidney disease (CKD), sponsored by None. Primary endpoint: Change in eGFR slope over study duration. Started Dec 2025; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on PACTR202511687575219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202511687575219.